The transport of the branched-chain amino acids L-leucine, L-valine, and L-isoleucine in Escherichia coli K-12 is mediated by several kinetically and genetically distinct systems (1, 8, 9, 14, 18) . The high-affinity, osmotic shock-sensitive uptake of leucine includes the LIV-I transport system requiring the LIV binding protein (livJ) and the leucine-specific system requiring the leucine-specific binding protein (7) (livK). Both binding protein systems require the product of the livH gene (1) and are repressible by L-leucine (13) . The low-affinity membranebound transport system for the branched-chain amino acids has been designated the LIV-II system (14, 18) . This latter system resists osmotic shock and has been observed in membrane vesicle preparations (18) . We have been using genetic approaches to determine the number of components of each system and their mutual interactions. In this report we describe the isolation and characterization of mutants lacking the IV-fl system and the properties of strains which possess the high-affinity systems but are missing the membrane-bound LIV-f system.
MATERIALS AND METHODS
Bacteria and phage. The bacterial strains used were all derivatives of E. coli K-12 and are listed in Table 1 . For tranaductions the phage PlCMclrlOO was used. Materials. Morpholinopropane sulfonic acid and nutritional supplements were obtained from Sigma Chemical Co., St. Louis, Mo. Media. Minimal medium for growth of cultures used in transport assays was the morpholinopropane sulfonic acid-based medium (MOPS-salts) described previously (12) . Amino acids and thymine were supplemented at 50 rAg/ml, except for L-leucine (see below). Unless otherwise noted, glucose was used at 0.2%. Luria broth with thymine was used for routine culture and for preparing cells for genetic crosses; recombinant selective agar plates were prepared with medium 56 as described previously (2) .
Genetic techniques. Cells were grown at 37°C in a New Brunswick Aquatherm shaker (New Brunswick Scientific Co., New Brunswick, N.J.), and growth was followed by measuring absorbance at 420 nm in a GCA/McPherson EU-700 spectrophotometer. Absorbance was converted to milligams of dry weight per milliliter by using the method of Koch (10) .
Culture conditions. Conjugations and P1 transductions were carried out as described by Miller (11) .
Transport assays. Transport of L-3H-amino acids was performed as described previously (1) . Strains were grown overnight in limiting glucose (0.02%)-MOPS-salts plus required supplements, and growth was renewed by adding glucose to 0.2%. After 1.5 mass doublings, the cells were harvested by centrifugation and washed. It was necessary to wash cells five times with MOPS-salts before assay to minimiz the extracellular leucine required by some of the strains used in these studies. The cells were suspended in MOPS-salts plus 0.2% glucose but minus required amino acids, to prevent net protein synthesis during the course of assay. After a 10-min adaptation, assays were initiated by adding 0.4 ml of cell suspension to 0.4 ml of L-3H-amino acid in MOPS-salts. A 0.4-ml sample was taken at an appropriate time, usually 10 a, and filtered through a 24-mm-diameter Millipore HA filter (0.45 pm; Millipore Corp., Bedford, Mass.), followed by a 5-ml wash of 10 mM potassium phosphate buffer, pH 7.2, at 37°C. Radioactivity was determined in a Packard liquid scintillation spectrometer, using a standard scintillation solution.
Determination of kinetic constants. For the studies reported here, biphasic kinetics were generally not observed when data were plotted by the double reciprocal method. For this simple situation we have employed the direct linear plot of Eisenthal and Cornish-Bowden (6) Isolation of mutants altered in the LIV-II system. Strain AE4017 (livH::Mu) was mutagenized with ethyl methane sulfonate as described by Miller (11) . The cells were washed twice in MOPS-salts and suspended in MOPS-salts supplemented with 0.02% glucose and 20,ug of L-leucyl-L-alanine per ml as a source of L-leucine that could enter the cells independent of the LIV-I and LIV-II uptake systems (9) . This technique avoided counterselecting mutants lacking both systems. After overnight growth at 37°C, glucose was added to 0.2%, and recovery was permitted for 1 mass doubling. The cells were washed by centrifugation three times and suspended in MOPS-salts supplemented with 0.2% glucose and 11.4 pM L-leucine. This level of L-leucine is below saturation of the residual LIV-II uptake system in strain AE4107. An initial cell density was chosen (absorbance at 420 nm, 0.04) which prior experiments showed would sustain 1.5 generations of logarithmic growth before L-leucine exhaustion. Ampicillin (final concentration, 20 pug/ml; Amcill-S; Parke, Davis & Co., Detroit, Mich.) was added immediately, and growth was permitted for 2 h at 37°C. Cells and cell debris were sedimented at 20,000 x g, washed once, and suspended in 0.02% glucose-MOPS-salts supplemented again with 20 pig of L-leucyl-L-alanine per ml. Another cycle of ampicillin enrichment was performed, the cell pellet was resuspended, and dilutions were plated on Luria broth with thymine. Colonies were replicated to glucose minimal agar containing either 3 ug of L-leucine per ml or 20 pg of L-leucyl-L-alanine per ml. Colonies showing growth on the latter plate but not on the former were cloned and checked for transport of L-leucine and Lalanine simultaneously as described previously (1) . The yield of mutants with normal L-alarmne transport but reduced L-leucine transport was 2%. Representatives of two phenotypic classes (strains AE410709 and AE4107012) were chosen for further study.
RESULTS
Mutants defective in the LIV-H uptake system. Two phenotypically distinguishable mutants unable to grow on 3 pug of L-leucine per ml were isolated as described above. Table 2 shows that they differ in their ability to utilize exogenous L-leucine. Strain AE410709 requires a relatively high (100 pug/ml) plate concentration of L-leucine to grow, and strain AE4107012 grows well on one-third (30 pg/ml) this level of leucine. We have designated the new mutant locus in VOL. 136, 1978 on July 10, 2017 by guest http://jb.asm.org/ Downloaded from strain AE410709 as livP9 and use it as the type strain for this locus. In the absence of evidence that the mutation in strain AE4107012 is allelic, we have designated this mutation as liv-12. Both mutants have specific defects in leucine uptake, since the transport of other amino acids has not been altered (Table 3) relative to the parent strain AE4107. Figure 1 shows the kinetics of L-leucine, Lvaline, and L-isoleucine uptake in both mutant strains. The uptake of L-leucine, L-vahne, and L-isoleucine is severely depressed relative to the parent strain AE4107 (Fig. 1 and Table 3 ) and in strain AE410709 (livP9) fails to demonstrate saturability up to 50 ,uM L-leucine. Strain AE4107012 (liv-12) differs only in that a minor saturable component for L-leucine is detectable ( Fig. 1 and Table 3 ) and presumably accounts for the lower threshold ofthis strain for L-leucine growth supplementation (Table 2) . Because both mutants show single-step reversion (frequency, approximately 10-') and are readily transduced to livP+, we infer that single mutations are responsible for the observed phenotypes and that these mutations specifically affect the residual LIV-II transport system of the parent strain AE4107.
Strains AE410709 (livP9), AE4107012 (liv-12), and AE4107 (livP) were transduced to leu+ and tested for excretion of L-leucine by spotting the strains on a lawn of strain AE41 (leu). After a 3-day incubation at 370C, both mutant strains showed cross-feeding, but the parent (livPr) did not. We conclude that the loss of both LIV-I and LIV-II systems resulted in a minor loss of ability to retain internal L-leucine.
Properties of the LIV-I system in the absence of the LIV-II system. Because livHN is cotransducible with mat' (1) (Fig. 2) and livP9 is not (see below), it was possible to construct strains carrying either livP9 or liv-12 mutations in a livHi background, which would allow the LIV-I system to be studied in the absence of the LIV-I system. Table 2 shows that strains AE137
(livH' liv-12) and AE166 (livH+ livP9) have regained the ability to grow on low levels of Lleucine, as well as the ability to use D-leucine as a source of L-leucine, a property requiring the high-affinity leucine-specific transport system (1) . Figure 3 shows that L-leucine uptake in strain AE166 (livH+ livP9) saturates at low concentrations of L-leucine, which would be expected of the high-affinity LIV-I and leucinespecific systems operating alone and not characteristic of the LIV-II uptake system operating alone (strain AE4107 livH::Mu). The additive uptake of leucine through the LIV-I, leucinespecific, and LIV-Il transport systems is illustrated in the wild-type strain AE41. The kinetics of strain AE137 (livHi liv-12) are similar to those for strain AE166, but we have omitted them for clarity. Table 4 shows the low Km for L-leucine uptake of strain AE137 (livHi liv-12), as would be expected for the high-affinity LIV-I and leucine-specific systems operating in the absence of the LIV-I system. We conclude that, because the LIV-I and leucine-specific systems function normally in the absence of a functional LIV-I system, and vice versa, the binding protein-mediated systems do not require the oper- ation of the membrane-bound LIV-II system; that is, the two types of systems can operate independently. When wild-type strains (livH+ livP+) or strains deficient in the high-affinity uptake systems only (livH livP+) are converted to spheroplasts with lysozyme-ethylenediaminetetraacetic acid treatment, residual uptake of leucine through the LIV-II system can be demonstrated (data not shown). However, strains of the genotypes livH livP or livH+ livP lose all detectable leucine uptake after conversion to spheroplasts, supporting the hypothesis that the livP gene product is an essential component of the osmotic shock-resistant LIV-II system.
Mapping of livP9 and liv-12. Genetic mapping in strains AE410709 (livH::Mu livP9) and AE4107012 (livH::Mu liv-12) is complicated by the fact that selection or screening for the ability to grow on low levels of L-leucine does not discriminate between livH' and livP+. These complications are the result of the independent functioning of each system and the ability of each isolated system to utilize exogenous L-leucine efficiently ( Table 2 ). (3) . The positions of livH and lstR have been reported previously (1, 2 duce livH::Mu with malT" in a malT derivative of strain KL14. When the livH+ donor was used, two classes of recombinants were observed. Those recombinants which acquired D-leucine utilization had acquired the livH' allele of the donor, regardless of the disposition of livP9 or liv-12, which are technically difficult to detect. The second class (livH::Mu livP+) is unambiguous because these recombinants had not acquired D-leucine utilization and had retained the livH::Mu allele of the recipient. If interference of crossing over is not significant, an equal proportion (14% in the case of AE410709) of livP+ can be assumed to be present in the livH+ class of recombinants as in the livH class. For strain AE410709, then, the frequency of livP+ (2 x 14.1% = 28.2%) is lower than the frequency of IivH' (85.9%). Similarly, for strain AE4107012 the frequency of liv+-12 (2 x 16.5% = 33%) is lower than that of IivH' (83.5%). Because the mating was uninterrupted, the declining gradient of trasnmission of markers from the point of origin of the Hfr (Fig. 2) indicates that livP9 and liv-12 are distal to livH. An interrupted mating using the same strains verified that livP is not located between the point of origin of strain KL14 and malT (data not shown). Table  5 also shows that, when the frequency of xyl+ recombinants was assessed among the livH::Mu livP" or liv+-12 recombinant class, the donor marker (xyl+) was underrepresented in the progeny (4% xyl+ compared with 10.1% xyl). This suggests thtat livP9 and liv-12 are located between livH and xyl (Fig. 2) . When P1 transducing phage were prepared on strain AE91 (malt livH::Mu livP+) and used to transduce strain AE410709 (malT livH::Mu livP9) to livP+ (growth on 3 pg of L-leucine per ml) without complication from the livH allele, no detectable cotransduction of mar' was observed (<1%). Reciprocally, ifmat" was the selected marker, livP+ cotransductants were not observed (<1%). Identical results were obtained with strain AE4107012 as recipient. Although it appears that livP and malT are not contransducible, we recognize that livP and malT are probably bracketing the Mu insertion of the livH::Mu donor, a circumstance which would lower their apparent linkage by the size of the Mu genome (30% of the transducing capacity of P1). Negative results were also obtained when the cotransduction ofxyl and livP was tested. Because there is a paucity of easily manipulated markers in the livH--xyl region (3) and difficulties exist in the genetics of this region (4), precise mapping will require extensive strain constructions.
The linkage of livP9 with liv-12 was examined by transduction with P1 phage. The recipient was strain AE410709 (livH::Mu livP9 malT). Donor phage was grown on strains AE91 (livH::Mu livP+ maiT) and AE125 (livH::Mu liv-12 malT). For each donor malT' and livP+ (ability to grow on 5 ,ug on L-leucine per ml) transductants were independently selected; malT' thus served as a control on the efficiency of transduction. In the case where the donor carried livP, the ratio of malT+ to livur transductants was 0.033 (1,100:37). When the donor carried liv-12, no livPr transductants were observed (950 malT+ transductants scored). We conclude that, because crossover between liv-12 and livP9 is rare, these two loci are closely linked. The reason for the low efficiency oftransduction of livP+ relative to malT+ is not apparent; the efficiency was not significantly improved by allowing growth before plating on selective medium. Complementation tests will be required to determine whether liv-12 and livP9 are alleles. DISCUSSION The mutation livH results in the loss of highaffinity uptake of L-leucine through the LIV-I and L-leucine-specific systems in E. coli K-12, although the binding proteins are unaltered (1) . The residual uptake has been identified as the LIV-II system, by the criteria of ligand specificity (L-leucine, L-vahne, and L-isoleucine with Km's of uptake in the 4-to 7-,uM range) and resistance to L-threonine inhibition (2) . This system has been characterized previously by ourselves and others (8, 14, 18) in wild-type strains. A system with similar specificity and Km values, but sensitive to L-threonine inhibition, has been reported by Guardiola and co-workers (9) . We have failed to confirm these results, because in all of our mutant strains lacking the high-affinity systems or in wild-type cells in which high-affinity systems are repressed by L-leucine, residual uptake of L-leucine is completely resistant to Lthreonine inhibition (2) .
Mutant strains selected from a livH back- Because the high-affinity binding protein-mediated leucine uptake systems and the LIV-II system operate in the mutational absence of each other (Fig. 3) , we infer that they are parallel systems, that is, the leucine-binding proteins probably do not operate by changing the affinity of the LIV-II system as has been suggested for another binding protein transport system, the mgl system (15) . The data do not exclude the possibility that one or more as-yet-unidentified components are shared. We have, in fact, obtained some indications that a common component may exist for the LIV-I and LIV-II systems. Certain azaleucine-resistant mutants which have not been characterized further were defective in both systems (Rahmanian and Oxender, unpublished data). In addition, the mutation brnR6(Am) has also been reported by Guardiola et al. (9) to affect both systems. Another report in the Japanese literature (quoted by Yamato and Anraku [19] ) suggests similar mutants. However, of 75 LIV-II mutants selected for this study, all regained LIV-I activity when livHi was introduced by transduction or sexduction (Anderson, unpublished observations), suggesting that pleiotropic mutations in LIV-I and LIV-II must be rare.
Our finding that strains lacking both LIV-I and LIV-II leucine transport systems are apparently unable to retain internal leucine and therefore become weak excretors of L-leucine are similar to results obtained with other transport systems. M. J. Whipp (Ph.D. thesis, University of Melbourne, Australia, 1977) has reported that mutants defective in specific uptake systems for cellular amino acids when transport systems are missing. Mutants selected for amino acid analog resistance frequently include transport defectives; if such strains fail to retain their respective metabolites, they might be expected to exhibit derepressed biosynthetic enzyme levels and could be misidentified as regulatory mutants.
